Coherus BioSciences (CHRS) Reports In-Line Q4 EPS
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.44 +2.13%
EPS Growth %: +23.5%
Financial Fact:
Cost of goods sold: 219.53M
Today's EPS Names:
RJET, DGICA, NEXT, More
EPS Growth %: +23.5%
Financial Fact:
Cost of goods sold: 219.53M
Today's EPS Names:
RJET, DGICA, NEXT, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($0.34), in-line with the analyst estimate of ($0.34). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $14.16 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Core Scientific Inc. (CORZ) to Buy
- Patrick Industries (PATK) Misses Q2 EPS by 9c
- Citadel buys AI stock portfolio from Situational Awareness fund - WSJ
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
